Although guidelines recommend combining long-acting bronchodilators in COPD, data are
limited. We examined the clinical efficacy and safety of formoterol, tiotropium and the …

Combined use of β 2-agonists and anticholinergic bronchodilators may have
complementary benefits in patients with chronic obstructive pulmonary disease (COPD). The …

Adding a long-acting β2-agonist (LABA) by dry powder inhaler (DPI) to tiotropium provides
significantly increased and sustained bronchodilation in chronic obstructive pulmonary …

We conducted a randomized, crossover trial with tiotropium 18μg once daily (group A), and
formoterol 12μg twice daily (group B) over a 5-day period for each drug, with a 10-day …

Bronchodilators are central in symptomatic management of all stages of COPD. For patients
whose COPD is not sufficiently controlled by monotherapy, combining an inhaled …

AIM: To determine which timing of therapy with formoterol (FOR) and/or tiotropium (TIO)
shows the greater and more continuous functional improvement during 24h in patients with …

This study compared the bronchodilator effects of tiotropium, formoterol and both combined
in chronic obstructive pulmonary disease (COPD). A total of 71 COPD patients (mean forced …

The aim of this double-blind, double-dummy, cross-over, randomized, pilot study was to
compare the acute bronchodilator efficacy of a single dose of formoterol with that of …

PURPOSE: Current guidelines support using in combination more than one class of long-
acting bronchodilator for COPD patients whose symptoms are not controlled by mono …

Background A 6-week, multicenter, randomized, double-blind, parallel-group study was
conducted in patients with COPD to compare lung function improvements of tiotropium, 18 …